Impact of Gonadotrophin REceptor Polimorphisms on the Relationship Between Serum AMH and Ovarian Response

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03388099

Acronym

GREPAMOR

Enrollment

296

Registered

2018-01-02

Start date

2018-01-11

Completion date

2019-12-18

Last updated

2019-12-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

antimüllerian Hormone and Gonadotrophin Receptor Polymorphism as Predictors of Ovarian Response

Keywords

gonadotrophin receptor polymorphism, antimüllerian hormone, ovarian response, ovarian stimulation

Brief summary

Aim of study: To compare the relationship between serum AMH and ovarian response for IVF with the GnRH antagonist protocol in patients who are carriers of FSH and/or LH receptor polymorphisms with those that are not.

Detailed description

Serum AMH has shown to have a high predictive capability of the ovarian response to stimulation for IVF. On the other hand, patients who are carriers of polymorphisms in the FSH and LH receptors, have shown to need higher doses of gonadotrophins for ovarian stimulation. The proportion of carriers has been described to be around 20% of the population. Nevertheless, the determination of these polymorphisms is not performed in routine practice. It is unknown if their presence affects to the relationship between serum AMH levels and ovarian response. This is a prospective, single center, non-interventional, cohorts study.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 45 Years

Healthy volunteers

Inclusion criteria

* 18-45 years of age presenting to IVF clinic * BMI of 18-35 kg/m2 * Having been tested for serum AMH with the Elecsys assay * Being planned to undergo ovarian stimulation cycle for IVF with the GnRH antagonist protocol * Signed written informed consent or waiver

Exclusion criteria

* Current or past disease affecting ovaries, gonadotropin or sex steroid * Current hormone therapy

Design outcomes

Primary

Measure	Time frame	Description
Gonadotrophin receptor polymorphisms and ovarian response and AMH value	1 year	To compare the relationship between serum AMH and ovarian response for IVF with the GnRH antagonist protocol in patients who are carriers of FSH and/or LH receptor polymorphisms with those that are not.

Secondary

Measure	Time frame	Description
polymorphisms in the FSH receptor (FSHR) variant N680S	1 year	To define the incidence of carriers of polymorphisms in the FSH receptor (FSHR) variant N680S (homozygous and heterozygous) among women undergoing ovarian stimulation for IVF.
polymorphisms in the LH receptor (LHR) variant N312S	1 year	To define the incidence of carriers of polymorphisms in the LH receptor (LHR) variant N312S (homozygous and heterozygous) among women undergoing ovarian stimulation for IVF.
Doses of gonadotrophin needed and polymorphisms	1 year	To analyse the doses of gonadotrophins needed for stimulation on each group of patients

Countries

Spain

Outcome results